Newsbenzinga
Axsome Therapeutics Says FDA Accepts NDA For AXS-12 For Treatment Of Cataplexy In Narcolepsy; PDUFA Target Action Date Set May 1, 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…